Investment Stage – Series A
PredictImmune aims to improve outcomes for patients by guiding treatment choices. Their vision is providing the tools that guide personalised medicine in inflammatory disease.
Spex Capital Ltd. (SPEX), registered in England and Wales, is authorised and regulated by the Financial Conduct Authority having Firm Reference Number 963796.
©2023 · Spex Capital
©2022 · Spex Capital